# Study of Vemurafenib, Carboplatin, and Paclitaxel

> **NCT01636622** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01636622
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-09
- **Primary completion:** 2020-04-21
- **Final completion:** 2020-04-21
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636622, "Study of Vemurafenib, Carboplatin, and Paclitaxel". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01636622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*